Crescom

(Photo: Crescom's CEO Jae Joon Lee(left), Ahngook Pharmaceutical's director Hee-Sung Chae _ ⓒ Crescom Co., Ltd.)

(Date: March 3, 2023) 

Crescom Co., Ltd., a company specializing in artificial intelligence medical image analysis solutions, has signed a joint sales contract for the MediAI-BA with Ahngook Pharmaceutical Co., Ltd.

Crescom's MediAI-BA is an artificial intelligence growth plate analysis solution that applies a hybrid method developed by Crescom, which complements the weaknesses of GP and TW3, widely used bone age reading techniques worldwide, and integrates only the strengths. It was approved by the MFDS(Ministry of Food and Drug Safety) in March 2020 and was also published in SCI-level international academic journal.

Through this contract, Hee-Sung Chae, the director of Ahngook Pharm., said, “I am delighted to further strengthen the digital healthcare business based on the business partnership with Crescom. And we will contribute to improving accessibility and treatment efficiency of children and adolescents through the introduction of excellent products.”.

Jae Joon Lee, CEO of Crescom, said, “MediAI-BA is currently being used very actively in around 250 clinics and hospitals by improving the efficiency and accuracy of doctors' growth plate bone age analysis in children and adolescents. Through the contract with Ahngook Pharm., we expect to be able to help more medical institutions with a timely, quick and accurate reading in the medical field.” Also, he said "In order to contribute to the healthy growth of children and adolescents, Crescom plans to expand into a more advanced growth analysis service. In addition to MediAI-BA, based on our excellent technology, we will expand the use of artificial intelligence medical solutions in the clinical field that are specialized in musculoskeletal image analysis, such as ▲ MediAI-FX(Automatic detection of fracture region and analysis of fracture probability which can read even difficult-to-read scaphoid fractures), ▲ MediAI-OA(knee arthritis severity automatic analysis solution), and ▲ MediAI-AS(ankylosing spondylitis automatic evaluation solution). We will actively pursue our business strategy continually. "